CliffBio
small molecule

METHOTREXATE SODIUM

METHOTREXATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETHOTREXATE SODIUM
Active ingredientMETHOTREXATE SODIUM
StrengthEQ 50MG BASE/2ML (EQ 25MG BASE/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 1999
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.